Toronto Dominion Bank Sells 1,392 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Toronto Dominion Bank reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 2.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 54,267 shares of the medical research company’s stock after selling 1,392 shares during the period. Toronto Dominion Bank’s holdings in IQVIA were worth $11,474,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc boosted its holdings in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares in the last quarter. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA during the second quarter worth approximately $27,000. Itau Unibanco Holding S.A. bought a new position in shares of IQVIA in the 2nd quarter worth $29,000. Rise Advisors LLC acquired a new stake in IQVIA in the 1st quarter valued at $31,000. Finally, Riverview Trust Co bought a new stake in IQVIA during the 1st quarter valued at $32,000. Institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.60% of the stock is owned by corporate insiders.

IQVIA Stock Performance

NYSE IQV opened at $234.56 on Friday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The company has a market capitalization of $42.74 billion, a PE ratio of 32.04, a price-to-earnings-growth ratio of 2.26 and a beta of 1.49. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The company has a 50-day simple moving average of $241.29 and a 200 day simple moving average of $233.69.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. During the same quarter in the previous year, the firm posted $2.22 EPS. IQVIA’s revenue was up 2.3% on a year-over-year basis. On average, research analysts predict that IQVIA Holdings Inc. will post 10.25 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on IQV shares. Robert W. Baird lifted their price objective on shares of IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a report on Friday, September 20th. Royal Bank of Canada started coverage on IQVIA in a report on Wednesday, September 4th. They set an “outperform” rating and a $275.00 price objective for the company. Truist Financial raised their target price on IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Argus upgraded IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Finally, Barclays raised their price objective on IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. Five equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $267.00.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.